Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vonoprazan dual therapy vs bismuth-containing quadruple therapy for first-line Helicobacter pylori eradication
ChiCTR2100044092Phase 4Recruiting
- Sponsor
- Army Medical Center
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of vonoprazan in Helicobacter pylori infection, chronic gastritis, gastric ulcer and 1 more (2 arms), sponsored by Army Medical Center. Primary endpoint: Helicobacter pylori eradication rate. Started Apr 2021; status: recruiting.
02
Drugs
vonoprazan
03
Conditions
Helicobacter pylori infectionchronic gastritisgastric ulcerduodenal ulcer
Beyond the preview
Go deeper on ChiCTR2100044092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100044092.